Stivarga 40 mg Alternative – Regora (Regorafenib) 40 mg Tablet | Beacon Pharmaceuticals
Regora 40 mg (Regorafenib) Tablet by Beacon Pharmaceuticals. Reference brand: Stivarga. multikinase inhibitor; used in selected previously treated colorectal cancer, GIST and liver cancer. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Regora 40 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Regorafenib. Stivarga is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Regora vs Stivarga – Reference Brand Comparison
Stivarga is a recognized reference brand associated with Regorafenib. Regora is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Regora. Active ingredient: Regorafenib. Strength: 40 mg. Dosage form: Tablet. Therapeutic class: multikinase inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Regorafenib is used in selected previously treated colorectal cancer, GIST and liver cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Regorafenib Works
Regorafenib blocks multiple tumor-associated kinases. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 40 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Regorafenib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include serious liver toxicity, hand-foot reactions and bleeding. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include serious liver toxicity, hand-foot reactions and bleeding. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Regora Listed as an Alternative to Stivarga?
The comparison helps identify another listed brand containing Regorafenib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Regora. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Stivarga. Generic: Regorafenib. Strength: 40 mg. Dosage form: Tablet.
Frequently Asked Questions
What is Regora 40 mg? It is a tablet containing Regorafenib 40 mg according to the supplied Beacon price list. What is it used for? Regorafenib is used in selected previously treated colorectal cancer, GIST and liver cancer, subject to specialist assessment. Can it replace Stivarga? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Regorafenib |
|---|---|
| Strength | 40 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Avastin 100 mg Alternative – Bevixa (Bevacizumab) 100 mg IV infusion | Incepta Pharmaceuticals
Bevixa 100 mg (Bevacizumab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Avastin (Roche).
Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Avastin 400 mg Alternative – Bevixa (Bevacizumab) 400 mg IV infusion | Incepta Pharmaceuticals
Bevixa 400 mg (Bevacizumab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Avastin (Roche).
Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lonsurf 15 mg / 6.14 mg Alternative – Trifluxen (Trifluridine 15 mg + Tipiracil 6.14 mg) 15 mg / 6.14 mg Tablet | Everest Pharmaceuticals
Trifluxen 15 mg / 6.14 mg (Trifluridine 15 mg + Tipiracil 6.14 mg) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lonsurf (Taiho Oncology). It belongs to the trifluridine/tipiracil combination class and is used in selected previously treated metastatic colorectal cancer and other authorized settings.
Active ingredient: Trifluridine 15 mg + Tipiracil 6.14 mg
Strength: 15 mg / 6.14 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Stivarga 40 mg Alternative – Regocent (Regorafenib) 40 mg Tablet | Incepta Pharmaceuticals
Regocent 40 mg (Regorafenib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Stivarga (Bayer).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals
Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.
Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.